Citations

Clear

4847 citation(s) found for "Tu, Eric".

Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.
Goss, Paul E., Ingle, J. N., Alés-Martínez, JE, Cheung, Anthony, Chlebowski, Rowan T. , McTiernan, Anne , Robbins, John, Sarto, Gloria E., Garber, J. E. , Fabian, Carol J. , Maunsell, Elizabeth, Farmer, Pierre, Wactawski‐Wende, Jean , Johnson, Karen , Martin, L., Winquist, Eric , Pujol, Pascal , Gelmon, Karen A. , Tu, Dongsheng , Richardson, Harriet

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 18_suppl | Pages: LBA504-LBA504

10.1200/jco.2011.29.18_suppl.lba504 Get It

LBA504 Background: Limited efficacy and serious toxicities have limited uptake of tamoxifen or raloxifene as preventatives of breast cancer. Aromatase inhibitors (AIs) prevent contralateral breast cancers more than tamoxifen in adjuvant trials and have fewer serious side effects. This is the first report of an AI used in primary prevention. Methods: NCIC CTG MAP.3 is a randomized trial designed to detect a 65% reduction in annual incidence of invasive breast cancer (IBC) on exemestane (E) versus placebo (P). Eligible postmenopausal women had ≥ one of the following risk factors: Gail score >1.66%, prior ADH, ALH, LCIS or DCIS with mastectomy, age over 60. Health-related and menopause-specific quality of life (QOL) were assessed by SF-36 and MENQOL questionnaires. Results: From 2004-2010, 4,560 women were randomized: age 62.5 yrs (37-90); Gail Score 2.3 % (0.6-21); BMI 28.0 kg/m2 (15.9-65.4). Risk factors included: age >60 yrs (49%); Gail score >1.66 (40%); and prior ADH, ALH, LCIS or DCIS with mastectomy (11%). At median follow-up of 35 months there were 11 IBCs on E and 32 on P (annual incidence 0.19% vs 0.55%; HR= 0.35, 95% CI 0.18-0.70, p = 0.002); ductal (10E/27P), lobular (1E/5P). Most tumors were ER positive (7E/27P); Her2/neu negative (10E/26P); TNM stage T1 (8E/28P), N0 (7E/22P), M0 (11E/30P). E was superior in all subgroups: by Gail score, age, BMI, prior LCIS and DCIS. The annual incidence rate of IBC or DCIS was 0.35% E and 0.77% P (HR=0.47;95% CI 0.27-0.79; p = 0.004) based on 64 IBCs or DCISs (20E/44P). Clinical bone fractures, osteoporosis, hypercholesterolemia or cardiovascular events were equal in both arms. No clinically meaningful differences in QOL were detected. Conclusions: Exemestane significantly reduced invasive and pre-invasive breast cancers in postmenopausal women at increased risk for breast cancer with no serious toxicities. Exemestane should be considered a new option for primary prevention of breast cancer. Supported by the Canadian Cancer Society; Pfizer Inc. PEG supported in part by Avon Foundation.
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Gonçalves, Rodrigo , Sanati, Souzan , Creighton, Chad J. , DeSchryver, Katherine, Crouch, Erika C., Brink, Amy, Luo, Jingqin , Yu, Tao , Budd, G. Thomas , Silverman, Paula , Esserman, Laura J. , Cynthia, X. , Unzeitig, Gary, Whitworth, Pat W. , Babiera, Gildy V., Guenther, J. Michael, Dayao, Zoneddy , Ota, David M., Leitch, Marilyn , Allred, D. Craig, Ellis, Matthew J. , Hoog, Jeremy , Crouch, Erika, Barnes, Michael, Dowsett, Mitchell, Winer, Eric, Esserman, Laura, Carey, Lisa, Ma, Cynthia X., Pluard, Timothy , Whitworth, Pat, Babiera, Gildy, Ota, David, Olson, John A. , Hunt, Kelly, Suman, Vera J. , Watson, Mark A. , Barnes, Michael , Dowsett, Mitch , Winer, Eric P. , Carey, Lisa A. , Hunt, Kelly K. , Esserman, Laura J , Luo, Jingqin

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 35 | Issue: 10 | Pages: 1061-1069

10.1200/jco.2016.69.4406 | PMID 28045625 Get It

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 determination after 2 to 4 weeks of AI. If the Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy. A pCR rate of > 20% was the predefined efficacy threshold. In patients who completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence differed by PEPI = 0 score (T1 or T2, N0, Ki67 < 2.7%, ER Allred > 2) versus PEPI > 0 disease. Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%) of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI > 0 (recurrence hazard ratio [PEPI = 0 v PEPI > 0], 0.27; P = .014; 95% CI, 0.092 to 0.764). Conclusion Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant proliferation. The optimal therapy for these patients should be further investigated. For patients with PEPI = 0 disease, the relapse risk over 5 years was only 3.6% without chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A Phase III Study; clinical trial information: NCT01953588).
Reducing Iodine Contrast Volume in CT Angiography of the Abdominal Aorta Using Integrated Tube Potential Selection and Weight-Based Method Without Compromising Image Quality
Vasconcelos, Rogerio N., Vrtiska, Terri J., Foley, Thomas A. , Macedo, Thanila A. , Cardona, Juan C. Montoya, Williamson, Eric E. , Vasconcelos, Rogerio, McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | February 22, 2017 | Volume: 208 | Issue: 3 | Pages: 552-563

10.2214/ajr.16.16613 | PMID 28225687 Get It

Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma
Dasari, Surendra , Nowakowski, Grzegorz S. , Wieben, Eric D. , Boddicker, Rebecca L., Luchtel, Rebecca A. , Wang, Xueju, Lazaridis, Konstantinos N. , Wang, Xueju , Kadin, Marshall E. , Feldman, Andrew L.

Mayo Clinic

Oncotarget | February 22, 2017 | Volume: 8 | Issue: 16 | Pages: 26245-26255

10.18632/oncotarget.15441 | PMID 28412739 Get It

Reply
Maciel, Gabriel, Crowson, Cynthia S. , Matteson, Eric L. , Cornec, Divi, Cornec, Divi

Mayo Clinic

Arthritis Care & Research | February 19, 2017 | Volume: 70 | Issue: 6 | Pages: 953-954

10.1002/acr.23222 | PMID 28217854 Get It

Chondrocyte Attachment, Proliferation, and Differentiation on Three-Dimensional Polycaprolactone Fumarate Scaffolds
Wagner, Eric R. , Parry, Joshua A. , Dadsetan, Mahrokh, Bravo, Dalibel , Riester, Scott M. , Wijnen, André J. van , Yaszemski, Michael J. , Parry, Joshua, van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | February 18, 2017 | Volume: 23 | Issue: 13-14 | Pages: 622-629

10.1089/ten.tea.2016.0341 | PMID 28375818 Get It

Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry
Melloni, Chiara, Shrader, Peter, Carver, Joseph R. , Piccini, Jonathan P. , Thomas, Laine , Ansell, Jack , Go, Alan S. , Herling, Irving M., Yu, Anthony F. , Kowey, Peter R. , Fonarow, Gregg C. , Gersh, Bernard J. , Hylek, Elaine M. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | February 15, 2017 | Volume: 3 | Issue: 3 | Pages: 192-197

10.1093/ehjqcco/qcx004 | PMID 28838088 Get It

Abstract Aims The presence of cancer can complicate treatment choices for patients with atrial fibrillation (AF) increasing both the risk of thrombotic and bleeding events. Methods and results Using data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we aimed to characterize AF patients with cancer, to describe their management and to assess the association between cancer and cardiovascular (CV) outcomes. Among 9749 patients, 23.8% had history of cancer (57% solid malignancy, 1.3% leukaemia, 3.3% lymphoma, 40% other type, and 2.2% metastatic cancer). Patients with history of cancer were older, more likely to have CV disease, CV risk factors, and prior gastrointestinal bleeding. No difference in antiarrhythmic and antithrombotic therapy was observed between those with and without cancer. Patients with history of cancer had a significantly higher risk of death (7.8 vs. 4.9 deaths per 100 patient-years follow-up, P = 0.0003) mainly driven by non-CV death (4.2 vs. 2.4 per 100 patient-years follow-up; P = 0.0004) and higher risk of major bleeding (5.1 vs. 3.5 per 100 patient-years follow-up; P = 0.02) compared with non-cancer patients; no differences were observed in risks of strokes/non-central nervous system embolism (1.96 vs. 1.48, P = 0.74) and CV death (2.89 vs. 2.07, P = 0.35) between the two groups. Conclusion A history of cancer is common among AF patients with up to one in four patients having both. Antithrombotic therapy, rates of cerebrovascular accident, other thrombotic events and cardiac death were similar in AF patients with or without a history of cancer. Patients with cancer, however, were at higher risk of major bleeding and non-CV death.
Idiopathic Subglottic Stenosis: Long‐Term Outcomes of Open Surgical Techniques
Menapace, Deanna C., Modest, Mara C., Ekbom, Dale C. , Moore, Eric J. , Edell, Eric S. , Kasperbauer, Jan L.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 14, 2017 | Volume: 156 | Issue: 5 | Pages: 906-911

10.1177/0194599817691955 | PMID 28195821 Get It

ObjectivesIdiopathic subglottic stenosis (iSGS) is rare, and its cause remains elusive. Treatment options include empiric medical therapy and endoscopic or open surgery. We present our results for open surgical technique.Study DesignCase series with chart review (1978‐2015).SettingTertiary academic center.Subjects/MethodsThirty‐three patients (32 female; median age, 51 years) met inclusion criteria and underwent cricotracheal resection with thyrotracheal anastomosis, tracheal resection with primary anastomosis, or laryngotracheoplasty with rib grafting. Continuous variables were summarized using medians and ranges while categorical features are presented using frequency counts and percentages.ResultsSixteen patients (48%) underwent a single‐stage approach with immediate extubation or temporary intubation following surgery (median, 1 day; range, 1‐3 days). Seventeen patients (52%) underwent a double‐staged approach with a median time to decannulation of 35 days (range, 13‐100 days). Twenty‐four (73%) patients underwent a previous intervention. Median stay in the intensive care unit was 1 day (range, 0‐3 days), with a median hospital stay of 4 days (range, 2‐7 days). Recurrence requiring further surgical intervention was observed in 12 patients (36%). The median time to recurrence was 8 years over an average follow‐up of 9.7 years. The most common complaint following surgery was change in voice quality (fair to poor; n = 10; 30%).ConclusionsOpen surgery should be reserved for refractory cases of iSGS; cricotracheal resection with thyrotracheal anastomosis is the preferred open technique. Recurrence may occur after open treatment, highlighting the importance of long‐term follow‐up. Patients should be counseled about the potential for worsening voice quality with the open approach.
Impaired Left Ventricular Global Longitudinal Strain in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the RELAX Trial
McNulty, Steven E., Alenezi, Fawaz , Ersbøll, Mads , Oh, Jae K. , Lin, Grace , Redfield, Margaret M. , Semigran, Marc J., Anstrom, Kevin J. , DeVore, Adam D. , Vader, Justin M. , Lewis, Gregory D. , Hernandez, Adrian F. , Velazquez, Eric J.

Mayo Clinic

European Journal of Heart Failure | February 14, 2017 | Volume: 19 | Issue: 7 | Pages: 893-900

10.1002/ejhf.754 | PMID 28194841 Get It

Abstract Background While abnormal left ventricular (LV) global longitudinal strain (GLS) has been described in patients with heart failure with preserved ejection fraction (HFpEF), its prevalence and clinical significance are poorly understood. Methods and results Patients enrolled in the RELAX trial of sildenafil in HFpEF (LV ejection fraction ≥50%) in whom two-dimensional, speckle-tracking LV GLS was possible (n = 187) were analysed. The distribution of LV GLS and its associations with clinical characteristics, LV structure and function, biomarkers, exercise capacity and quality of life were assessed. Baseline median LV GLS was −14.6% (25th and 75th percentile, −17.0% and −11.9%, respectively) and abnormal (≥ − 16%) in 122/187 (65%) patients. Patients in the tertile with the best LV GLS had lower N-terminal pro-brain natriuretic peptide (NT-proBNP) [median 505 pg/mL (161, 1065) vs. 875 pg/mL (488, 1802), P = 0.008) and lower collagen IIIN-terminal propeptide (PIIINP) levels [median 6.7 µg/L (5.1, 8.1) vs. 8.1 µg/L (6.5, 10.5), P = 0.001] compared with the tertile with the worst LV GLS. There was also a modest linear relationship with LV GLS and log-transformed NT-proBNP and PIIINP (r = 0.29, P &lt; 0.001 and r = 0.19, P = 0.009, respectively). We observed no linear association of LV GLS with Minnesota Living with Heart Failure scores, 6-min walk distance, peak oxygen consumption, or expiratory minute ventilation/carbon dioxide excretion slope. Conclusions Impaired LV GLS is common among HFpEF patients, indicating the presence of covert systolic dysfunction despite normal LV ejection fraction. Impaired LV GLS was associated with biomarkers of wall stress and collagen synthesis and diastolic dysfunction but not with quality of life or exercise capacity, suggesting other processes may be more responsible for these aspects of the HFpEF syndrome.